Management of blood glucose in type 2 diabetes mellitus
- PMID: 19145963
Management of blood glucose in type 2 diabetes mellitus
Abstract
Evidence-based guidelines for the treatment of type 2 diabetes mellitus focus on three areas: intensive lifestyle intervention that includes at least 150 minutes per week of physical activity, weight loss with an initial goal of 7 percent of baseline weight, and a low-fat, reduced-calorie diet; aggressive management of cardiovascular risk factors (i.e., hypertension, dyslipidemia, and microalbuminuria) with the use of aspirin, statins, and angiotensin-converting enzyme inhibitors; and normalization of blood glucose levels (hemoglobin A1C level less than 7 percent). Insulin resistance, decreased insulin secretion, and increased hepatic glucose output are the hallmarks of type 2 diabetes, and each class of medication targets one or more of these defects. Metformin, which decreases hepatic glucose output and sensitizes peripheral tissues to insulin, has been shown to decrease mortality rates in patients with type 2 diabetes and is considered a first-line agent. Other medications include sulfonylureas and nonsulfonylurea secretagogues, alpha glucosidase inhibitors, and thiazolidinediones. Insulin can be used acutely in patients newly diagnosed with type 2 diabetes to normalize blood glucose, or it can be added to a regimen of oral medication to improve glycemic control. Except in patients taking multiple insulin injections, home monitoring of blood glucose levels has questionable utility, especially in relatively well-controlled patients. Its use should be tailored to the needs of the individual patient.
Comment in
-
How important is reaching blood glucose level goals?Am Fam Physician. 2010 Jul 15;82(2):100; author reply 101-2. Am Fam Physician. 2010. PMID: 20642260 No abstract available.
Similar articles
-
Sitagliptin: a novel drug for the treatment of type 2 diabetes.Cardiol Rev. 2007 Sep-Oct;15(5):264-71. doi: 10.1097/CRD.0b013e318123f771. Cardiol Rev. 2007. PMID: 17700385 Review.
-
Cardiovascular manifestations of insulin resistance.Am J Ther. 2009 Sep-Oct;16(5):e14-28. doi: 10.1097/MJT.0b013e3180a724b3. Am J Ther. 2009. PMID: 19114874 Review.
-
Promising new approaches.Diabetes Obes Metab. 1999 May;1 Suppl 1:S41-8. Diabetes Obes Metab. 1999. PMID: 11220287 Review.
-
Treatment of metabolic syndrome.Expert Rev Cardiovasc Ther. 2004 Mar;2(2):213-28. doi: 10.1586/14779072.2.2.213. Expert Rev Cardiovasc Ther. 2004. PMID: 15151470 Review.
-
Therapy for type 2 diabetes mellitus.WMJ. 1998 Mar;97(3):49-54. WMJ. 1998. PMID: 9540451 Review.
Cited by
-
Highlighting the effects of high-intensity interval training on the changes associated with hypertrophy, apoptosis, and histological proteins of the heart of old rats with type 2 diabetes.Sci Rep. 2024 Mar 26;14(1):7133. doi: 10.1038/s41598-024-57119-6. Sci Rep. 2024. PMID: 38531890 Free PMC article.
-
Ag@AuNP-Functionalized Capillary-Based SERS Sensing Platform for Interference-Free Detection of Glucose in Urine Using SERS Tags with Built-In Nitrile Signal.Molecules. 2023 Dec 5;28(24):7939. doi: 10.3390/molecules28247939. Molecules. 2023. PMID: 38138429 Free PMC article.
-
Mindsets and self-efficacy beliefs among individuals with type 2 diabetes.Sci Rep. 2023 Nov 21;13(1):20383. doi: 10.1038/s41598-023-47617-4. Sci Rep. 2023. PMID: 37990071 Free PMC article.
-
Vitamin D improves the antidiabetic effectiveness of aerobic training via modulation of Akt, PEPCK, and G6Pase expression.Diabetol Metab Syndr. 2023 Sep 9;15(1):184. doi: 10.1186/s13098-023-01158-y. Diabetol Metab Syndr. 2023. PMID: 37689713 Free PMC article.
-
A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors.CPT Pharmacometrics Syst Pharmacol. 2023 Apr;12(4):487-499. doi: 10.1002/psp4.12934. Epub 2023 Mar 8. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36890732 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
